



Canadian guideline inclusion - Highest ranking for Cerebrolysin®

Cerebrolysin® inclusion in **Evidence-Based Review Stroke Rehabilitation (EBRSR)**
and in **Clinician's handbook**


Cerebrolysin®

Reconnecting Neurons.
Empowering for Life.

Best ranked drug in post-stroke recovery

Motor rehabilitation is essential

- Upper extremity complications are very common following stroke
- They can seriously impact the progress of rehabilitation
- Recovery has a **significant impact on quality of life and Activities of daily living (ADL)**



Evidence Reviews
Chapter 10



Clinician's Handbook
Section 4

Titel

Evidence-Based Review of Stroke Rehabilitation
funded by Canadian Partnership for Stroke Recovery (CPSR)



Website

www.ebrsr.com

Author

Prof. Dr. Robert Teasell – Global Leader in Neurorehabilitation research

*in Clinician's handbook without any negativ comments

ABBREVIATED PRESCRIBING INFORMATION – Cerebrolysin. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, pre-clinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics. (03.06.2016)

Copyright © 2020 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria

CERE/INT/10/2020/20